Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
286.98
-6.47 (-2.20%)
At close: May 15, 2026, 4:00 PM EDT
293.80
+6.82 (2.38%)
After-hours: May 15, 2026, 7:34 PM EDT
Alnylam Pharmaceuticals Revenue
Alnylam Pharmaceuticals had revenue of $1.17B in the quarter ending March 31, 2026, with 96.43% growth. This brings the company's revenue in the last twelve months to $4.29B, up 82.57% year-over-year. In the year 2025, Alnylam Pharmaceuticals had annual revenue of $3.71B with 65.19% growth.
Revenue (ttm)
$4.29B
Revenue Growth
+82.57%
P/S Ratio
8.94
Revenue / Employee
$1,714,769
Employees
2,500
Market Cap
38.32B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.71B | 1.47B | 65.19% |
| Dec 31, 2024 | 2.25B | 419.95M | 22.97% |
| Dec 31, 2023 | 1.83B | 790.87M | 76.23% |
| Dec 31, 2022 | 1.04B | 193.13M | 22.88% |
| Dec 31, 2021 | 844.29M | 351.43M | 71.31% |
| Dec 31, 2020 | 492.85M | 273.10M | 124.28% |
| Dec 31, 2019 | 219.75M | 144.84M | 193.36% |
| Dec 31, 2018 | 74.91M | -15.00M | -16.69% |
| Dec 31, 2017 | 89.91M | 42.75M | 90.66% |
| Dec 31, 2016 | 47.16M | 6.06M | 14.75% |
| Dec 31, 2015 | 41.10M | -9.46M | -18.72% |
| Dec 31, 2014 | 50.56M | 3.39M | 7.20% |
| Dec 31, 2013 | 47.17M | -19.56M | -29.31% |
| Dec 31, 2012 | 66.73M | -16.03M | -19.37% |
| Dec 31, 2011 | 82.76M | -17.28M | -17.28% |
| Dec 31, 2010 | 100.04M | -492.00K | -0.49% |
| Dec 31, 2009 | 100.53M | 4.37M | 4.54% |
| Dec 31, 2008 | 96.16M | 45.27M | 88.94% |
| Dec 31, 2007 | 50.90M | 23.97M | 89.00% |
| Dec 31, 2006 | 26.93M | 21.21M | 371.13% |
| Dec 31, 2005 | 5.72M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Regeneron Pharmaceuticals | 14.92B |
| BeOne Medicines AG | 5.70B |
| Incyte | 5.36B |
| argenx SE | 4.74B |
| Genmab | 3.90B |
| BioNTech SE | 3.23B |
| Royalty Pharma | 2.44B |
| Moderna | 2.23B |
ALNY News
- 4 days ago - Alnylam Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 5 days ago - Alnylam announces new analyses from HELIOS-B study of vutrisiran - TheFly
- 5 days ago - New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden - Business Wire
- 10 days ago - MBX Biosciences appoints Mark Soued as chief commercial officer. - TheFly
- 10 days ago - Alnylam to Webcast Presentations at Upcoming Investor Conferences - Business Wire
- 13 days ago - Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM - Business Wire
- 16 days ago - Alnylam price target raised to $370 from $360 at Morgan Stanley - TheFly
- 16 days ago - Alnylam price target lowered to $447 from $448 at Bernstein - TheFly